On Mar. 23, 2021, Omeros and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial had begun.

The I-SPY COVID-19 Trial was an adaptive platform trial that was to screen rapidly, in parallel, multiple promising agents in order to identify drugs that have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.

Narsoplimab is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement. It was the only complement inhibitor invited to participate in the I-SPY COVID-19 Trial.

Narsoplimab was administered under compassionate use to treat severely ill COVID-19 patients requiring mechanical ventilation, with impressive outcomes.

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery.